Merck is hoping to go where Pfizer, Takeda and Lundbeck were unable to with a phosphodiesterase 10A inhibitor, or PDE10A. The aim is to target an enzyme that could help retune the body’s neurotransmitter dopamine.
2 Likes
I don’t understand, have they made a new medication? I couldn’t see a name anywhere.
1 Like
They’re sending it to Vegas?
1 Like
Merck get $50 million for the ongoing Phase IIb of MK-8189
A new med.
Phase 2b trials of a drug based on the phosphodiesterase 10A inhibitor, or PDE10A. The aim is to target an enzyme that could help retune the body’s neurotransmitter dopamine." with trials of the drug at 8, 16 and 24mg.
They call it ‘MK- 8189’
1 Like
Another novel drug besides Ulotaront and Karxt? Exciting. I wonder why there’s suddenly so many new treatments coming up in this period.
2 Likes
It’ll never be in my price range. I know this because they say it helps with weight loss, which puts it in very high demand which means the prices skyrocket
2 Likes
This is so exciting. Hurry up I say
1 Like
If phase 2 results are expected in early 2024, then the drug Might pass Phase 3 and Might be approved around 2027, only if it works as the companies Hope.
2 Likes
Sounds interesting, ill read the article later. Hopefully better drugs do come out in future. Ideally drugs that get rid of psychosis and do nothing else.
That would be the best… seriously.
I wish I got the disease when these drugs came out…
Most useful line in the article
The aim is to target an enzyme that could help retune the body’s neurotransmitter dopamine.
So i wonder what they mean to that, i heard schizophrenics have an enlarged d2 receptor and thats what causes the auditory hallucinations
2 Likes